Evoxac

Evoxac is a brand name of cevimeline, approved by the FDA in the following formulation(s):

EVOXAC (cevimeline hydrochloride - capsule; oral)

• 
  Manufacturer: DAIICHI SANKYO CO
  
  Approval date: January 11, 2000
  
  Strength(s): 30MG ^[RLD][AB]

Has a generic version of Evoxac been approved?

A generic version of Evoxac has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Evoxac and have been approved by the FDA:

CEVIMELINE (cevimeline hydrochloride capsule; oral)

• 
  Manufacturer: APOTEX INC
  
  Approval date: August 25, 2011
  
  Strength(s): 30MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evoxac. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Composition and method for treating Sjoegren syndrome disease
  Patent 5,340,821
  Issued: August 23, 1994
  Inventor(s): Abe; Nobuaki & Takeshita; Yasuyoshi
  Assignee(s): Snow Brand Milk Products Co., Ltd.
  A composition for treating a Sjoegren syndrome disease is disclosed. The composition comprising derivative of spirooxathiolane-quinuclidine of the following formula (I), ##STR1## wherein Z is .dbd.CR.sup.1 R.sup.2, wherein R.sup.1 and R.sup.2 may be the same or different and each represents hydrogen, alkyl, cyclopentyl, cyclohexyl, aryl, diarylmethylol, or alkyl which may be substituted by one or more aryl groups, or an acid addition salt thereof, or an acid addition salt thereof, as an effective component. Especially effective is an administration of a hydrochloric acid addition salt of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine.
  
  Patent expiration dates:
  
  
  • July 7, 2013
    
    ✓ 
    Patent use: TREATING SJOEGREN SYNDROME
  
  

See also...

• Evoxac Consumer Information (Wolters Kluwer)
• Evoxac Consumer Information (Cerner Multum)
• Evoxac Advanced Consumer Information (Micromedex)
• Evoxac AHFS DI Monographs (ASHP)
• Cevimeline Consumer Information (Wolters Kluwer)
• Cevimeline Consumer Information (Cerner Multum)
• Cevimeline Advanced Consumer Information (Micromedex)
• Cevimeline Hydrochloride AHFS DI Monographs (ASHP)